Category Archives

MARAC Statements

In 2020, SCDAA’s Medical and Research Advisory Committee (MARAC) was formed to address community concerns about COVID-19. Since then, MARAC’s team of acclaimed sickle cell experts have provided important guidance on topics like gene therapy, vaccinations, infectious diseases and more. MARAC’s global reach helps inform sickle cell warriors, caregivers and providers across the world.

MARAC Leadership

  • Dr. Edward Donnell Ivy
    Chief Medical Officer

  • Dr. Crawford Strunk
    Vice Chief Medical Officer

MARAC Statement: Pfizer Inclacumab Announcement

  • August 15, 2025
  • Emma Day

August 15, 2025  – In a statement issued today, Pfizer announced the results of their Phase 3 THRIVE-131 study evaluating inclacumab.... Continue Reading

MARAC Statement: ASH Report on Exercise and SCT Crisis Risk

  • February 6, 2025
  • Emma Day

Feb. 5, 2025 – On January 30, 2025, the American Society of Hematology (ASH) published a report that found no evidence... Continue Reading

MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal

  • September 28, 2024
  • Emma Day

SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal 9/27/24 What is the news? Pfizer announced the withdrawal... Continue Reading

MARAC Statement: Parvovirus B19, Fever and Urgent Care

  • August 15, 2024
  • Emma Day

MARAC Statement: Parvovirus B19, Fever and Urgent Care Aug. 13, 2024 – More infections with parvovirus B19, also known as “fifth... Continue Reading

SCDAA Statement About Gene Therapy Approval

  • December 8, 2023
  • Emma Day

On Dec. 8, 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for sickle cell disease (SCD), Casgevy... Continue Reading

MARAC Statement: Health Insurance Coverage for MSD SCT

  • September 22, 2023
  • Emma Day

MARAC Statement: Health Insurance Coverage for Hematopoietic Stem Cell Transplant for Sickle Cell Disease from HLA-matched Sibling Donor (MSD HCT) Sept.... Continue Reading

MARAC Statement: Update About COVID

  • September 22, 2023
  • Emma Day

Sept. 16, 2023 – The worldwide pandemic of COVID-19 (SARS-CoV2) infections seem to have settled down, and we are now seeing... Continue Reading

MARAC Statement: Crizanlizumab (Adakveo)

  • July 7, 2023
  • Emma Day

July 7, 2023 – SCDAA’s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency’s (EMA) Committee for Medicinal... Continue Reading

MARAC Statement: Penicillin Shortage

  • February 7, 2023
  • Emma Day

Penicillin VK solution is suffering from intermittent supply shortages. This can affect children with sickle cell disease. Penicillin VK in liquid... Continue Reading

MARAC Statement on Influenza

  • December 7, 2022
  • Emma Day

December 6, 2022 — The Sickle Cell Disease Association of America (SCDAA) Medical and Research Advisory Committee (MARAC) shares the following:... Continue Reading